Hormonal
Tirzepatide administration is associated with a high frequency of gastrointestinal adverse events (nausea, diarrhea, vomiting) and injection-site reactions, with a median time to onset of 26 days, occurring predominantly during the dose-escalation phase.
If you start Tirzepatide, expect gastrointestinal issues like nausea or diarrhea, especially in the first month. These are common reasons for stopping treatment. Starting at the lowest dose (5mg) might help you tolerate the medication better, as higher doses are linked to later but potentially more severe onset of side effects. Monitor your symptoms closely during the first few weeks.
Common events included gastrointestinal disorders (nausea and diarrhea) and injection-site reactions. The median onset time was 26 days, with 50% of events occurring within the first month... The most common AEs leading to discontinuations were nausea, decreased appetite and decreased weight.
Why this rating
Real-world pharmacovigilance data (FAERS) is prone to reporting bias and lacks controlled dosing verification, though sample size is large.
Source
Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
Zhenpo Zhang et al. · Endocrine Connections · 2025
DOI 10.1530/ec-25-0205
More from this paper
- Older adults (≥65 years) experience adverse events from Tirzepatide significantly earlier (median 12 days) than younger adults (median 31 days), suggesting heightened sensitivity or earlier symptom reporting in this demographic.Moderate
- Tirzepatide use is associated with novel safety signals including belching, upper respiratory tract infections, and postmenopausal hemorrhage, which are not prominently featured in standard prescribing information.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →